Switzerland / What Novartis & Roche's Domestic Market Means to Them
The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based…
Cell & Gene Therapy
China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look…
Cell & Gene Therapy / Curing the Incurable: A New Age for Pharmacovigilance
Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on…
Cell & Gene Therapy / Collaborative Spirit
One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they…
In Conversation
Thomas D. Szucs, European Center of Pharmaceutical Medicine at the University of Basel; Hirslanden Private Hospital, Switzerland; Chairman, Helsana Group
Genomic medicine expert Professor Thomas D. Szucs explains what ignited his interest in the field and how payers and authorities are adapting to the strain on resources that genomic medicine can contribute to. Professor Szucs also evaluates the sustainability of personalized medicine and China’s rapid progress in the field. The evolution of genomic medicine needs to be accompanied…
Stefan Hendriks – Global Head Cell & Gene,…
Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he has put…
Nicolaus Kröger – President, European Society for…
Professor Nicolaus Kröger, president of the European Society for Blood and Marrow Transplantation (EBMT) introduces the multi-stakeholder GoCART Coalition and the impact that it stands to have on the cell…
Cell & Gene Therapy / Finding the Funding in France
France – one of the most influential countries in the development of gene therapy– still stands as a global…
USA / Navigating Increasingly Stormy Market Access Waters
Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including…
The Cell & Gene Therapy Market: Coming into Its Own
David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and…
Tackling the Talent Gap in Cell & Gene Therapy
Rare diseases and cell and gene therapy executive recruitment specialist Steve Smith outlines six key strategies…
Switzerland / What Novartis & Roche's Domestic Market Means to Them
The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based…
China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…